KLRA Fail-to-Deliver

Kailera Therapeutics, Inc. (KLRA) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $2.84B, listed on NASDAQ, employing roughly 145 people, carrying a beta of 0.00 to the broader market. Kailera Therapeutics is a clinical-stage biopharmaceutical company developing a diverse pipeline of next-generation therapies designed to treat obesity and related conditions. Led by Ronald C. Renaud Jr., public since 2026-04-17.

Fail-to-deliver (FTD) data from the SEC tracks settlement failures where shares were not delivered within the standard settlement period. Persistent FTDs may indicate naked short selling or settlement issues and are monitored by regulators.

Latest Date
2026-05-14
Latest FTD Quantity
13
Latest Price
$21.11
30-Day Avg FTD
7.6K
30-Day Total FTD
98.2K

Showing 13 days of SEC fail-to-deliver data for Kailera Therapeutics, Inc..

Learn how fails-to-deliver is reported and how to read the data →

Frequently asked KLRA fail to deliver questions

What is the latest KLRA fail-to-deliver count?
As of May 14, 2026, Kailera Therapeutics, Inc. (KLRA) fail-to-deliver quantity is 13 shares, with a 13-day average of 7.6K shares. The SEC publishes FTD data twice monthly: first-half data at month-end, second-half around the 15th of the following month.
What is the FTD aggregate net balance?
FTD figures represent the aggregate net balance in NSCC's Continuous Net Settlement (CNS) system, not the gross failed-share count. The published numbers run 2-6 weeks stale relative to the underlying settlement date.
How do KLRA FTDs affect options pricing?
Persistent FTDs flag hard-to-borrow conditions that distort put-call parity: in HTB names, synthetic long stock (long call + short put at the same strike) trades below the frictionless-parity price by approximately the borrow rebate. The discount equals the lending revenue forgone by holding the synthetic instead of actual shares. Reg SHO threshold-list inclusion follows from sustained FTD persistence.